Harbour Capital Advisors LLC Buys 1,611 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Harbour Capital Advisors LLC increased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 33.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,452 shares of the company’s stock after purchasing an additional 1,611 shares during the period. Harbour Capital Advisors LLC’s holdings in TransMedics Group were worth $446,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Driehaus Capital Management LLC lifted its holdings in shares of TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after purchasing an additional 202,867 shares in the last quarter. Principal Financial Group Inc. lifted its stake in TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after acquiring an additional 146,115 shares during the period. Hood River Capital Management LLC purchased a new stake in shares of TransMedics Group during the 2nd quarter valued at about $18,854,000. Canada Pension Plan Investment Board bought a new stake in shares of TransMedics Group in the second quarter worth approximately $16,086,000. Finally, Public Sector Pension Investment Board bought a new stake in shares of TransMedics Group in the third quarter worth approximately $11,079,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMDX has been the topic of several research reports. Robert W. Baird dropped their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Canaccord Genuity Group cut their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Finally, TD Cowen reduced their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

Insider Activity

In related news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.00% of the company’s stock.

TransMedics Group Trading Down 6.9 %

Shares of NASDAQ:TMDX opened at $64.05 on Tuesday. The stock has a 50 day moving average of $73.56 and a 200 day moving average of $120.20. The company has a market cap of $2.15 billion, a PE ratio of 68.14 and a beta of 2.12. TransMedics Group, Inc. has a 12-month low of $58.27 and a 12-month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period last year, the company earned ($0.12) earnings per share. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, equities research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.